IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme

• Published in: Gene 2015-01, Vol.554 (1), p.81-86
• Main Authors: Kalkan, Rasime, Atli, Emine İkbal, Özdemir, Muhsin, Çiftçi, Evrim, Aydin, Hasan Emre, Artan, Sevilhan, Arslantaş, Ali
• Format: Article
• Language: English
• Subjects: Adult; Age Factors; Biomarkers, Tumor - metabolism; Brain Neoplasms - diagnosis; Brain Neoplasms - genetics; Brain Neoplasms - mortality; DNA Methylation; DNA Modification Methylases - genetics; DNA Mutational Analysis; DNA Repair Enzymes - genetics; Exons; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioblastoma - diagnosis; Glioblastoma - genetics; Glioblastoma - mortality; Humans; IDH1 mutation; Isocitrate Dehydrogenase - genetics; Male; MGMT methylation; Middle Aged; MS-HRM; Mutation; Primary glioblastoma; Prognosis; Tumor Suppressor Proteins - genetics; Turkey
• ISSN: 0378-1119; 1879-0038
• DOI: 10.1016/j.gene.2014.10.027

To establish the frequency of IDH1 mutations and MGMT methylation in primary glioblastomas. We screened primary glioblastoma multiforme (GBM) in a population-based study for IDH1 mutations and MGMT methylation and correlated them with clinical data. IDH1 mutations were detected in 5 of 40 primary glioblastomas (12,5%). Primary GBM patients carrying IDH1 mutations were significantly younger, mean age of 41±5.06years, than patients with wild-type IDH1, mean age of 57±2,29years, p=0.011. The mean survival time of all GBM patients with and without IDH1 mutations was 19months (5 cases) and 16months (35 cases), respectively (p>0,05). MGMT methylation was detected in 13 of the 40 patients (32,5%). MGMT-promoter methylation did not correlate with overall survival (OS; p>0,05). In summary, our study is the first study to investigate the IDH1 mutation status and MGMT methylation in primary GBMs in Turkish population and confirmed IDH1 mutation as a genetic marker for also primary GBMs. Our data are still insufficient for definite ascertainment; and our preliminary results suggest: IDH1 status shows an association with younger age and there is a lack of association between IDH1 mutation and survival time. Furthermore MGMT promoter methylation had no prognostic value and lower frequency in primary glioblastomas. •In primary GBMs IDH1 mutations were associated with younger age.•MGMT methylation did not correlate with overall survival or younger age in primary GBMs.•In primary GBMs no association was detected between IDH1 mutation and survival time.